| API | Indication | Micronised / PSD | CEP | EU DMF | US DMF | JP DMF | KR DMF | CN DMF |
|---|---|---|---|---|---|---|---|---|
| Asenapine p | Schizophrenia and acute mania | • | ||||||
| Brexpiprazole | Schizophrenia and major depressive disorders | |||||||
| Brivaracetam | Antiepileptic | |||||||
| Clomethiazole | Insomnia | • | ||||||
| Eletriptan HBr p | Migraine | • | • | |||||
| Olanzapine p | Schizophrenia, psychosis | • | • | |||||
| Olanzapine pamoate (sterile) | Schizophrenia, psychosis | • | ||||||
| Quetiapine hemifumarate p | Schizophrenia, psychosis | • | • | • | ||||
| Risperidone p | Schizophrenia, psychosis | • | • | • | • | |||
| Rizatriptan benzoate p | Migraine | • | • | • | ||||
| Tetrabenazine | Parkinson disease | |||||||
| Tetrabenazine (+) | Parkinson disease | |||||||
| Zolmitriptan p | Migraine | • | • | • |
P = Patent applications/granted patents owned by Neuraxpharm
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / INKE. All rights reserved.